Cytokine News and Research

RSS

C-type lectin receptors play a role in SARS-CoV-2 infection

A new study published on the preprint server bioRxiv in August 2020 confirms and extends earlier findings showing that a type of sugar-based receptor on innate immune cells promotes the entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into other cells that carry the viral receptor, angiotensin-converting enzyme 2 (ACE2).

12 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

COVID-19 should be treated as an acute inflammatory disease, Massey scientist says

The COVID-19 pandemic has had detrimental effects on global infrastructure sectors, including economic, political, health care, education and research systems, and there is still no definitive treatment strategy for the disease.

5 Aug 2020

Eosinophils contribute to antiviral host defense mechanisms during influenza

Eosinophils residing in the airways of mice respond to influenza A virus infection through alterations in surface expression of various markers necessary for migration and cellular immunity responses, according to research published in the Journal of Leukocyte Biology by researchers from Le Bonheur Children's Hospital and the University of Tennessee Health Science Center.

5 Aug 2020

Stabilized prefusion spike vaccine candidate induces powerful immune response

A new research paper by scientists at Janssen Vaccines & Prevention BV, in the Netherlands and published on the preprint server bioRxiv* is based on the assumption that an effective vaccine against these infections will induce neutralizing antibodies and an immune response favoring Th1 immunity.

3 Aug 2020

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

Severe fatigue common in COVID-19, independent of disease severity

Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection often complain of fatigue, but now a new study shows that it also causes severe and frequent fatigue in those who recover after mild illness too.

2 Aug 2020

New simple way of detecting COVID-19 in blood plasma

Even as the COVID-19 pandemic claims increasing numbers of patients, testing numbers are rising in most nations at the leading edge. However, the current reverse transcriptase-polymerase chain reaction (RT PCR) testing is often unavailable and takes up to several days for results to arrive.

31 Jul 2020

Researchers report a liquid biopsy for COVID-19

A new study published on the preprint server medRxiv in July 2020 reports the potential of cell-free DNA as a marker of the severity of disease in COVID-19. This could help triage patients as well as provide a prognostic marker.

30 Jul 2020

Lab profiles differentiate MIS-C from severe COVID-19 in children

In the early days of the COVID-19 pandemic, the SARS-CoV-2 virus seemed only rarely to have serious complications in children.

30 Jul 2020

Clinical study evaluates potential of oral cancer drug to reduce respiratory symptoms of COVID-19

Researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Ohio State University Wexner Medical Center are conducting a new clinical trial to determine if an oral cancer drug called ibrutinib can also help patients with cancer or other immunocompromised conditions recover from COVID-19.

29 Jul 2020

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.

29 Jul 2020

Identification of MTK1 SAPKKK as new human oxidative stress sensor

In an aging society, various studies are being conducted to explore the relationship between active oxygen and aging-related diseases such as cancer, chronic inflammatory diseases, and metabolic syndrome.

28 Jul 2020

Computational analyses suggest new pathway for inflammatory response to SARS-CoV-2

Analyses of lung fluid cells from COVID-19 patients conducted on the nation's fastest supercomputer point to gene expression patterns that may explain the runaway symptoms produced by the body's response to SARS-CoV-2.

28 Jul 2020

FDA approves first CAR T-cell therapy for patients with mantle cell lymphoma

The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments.

28 Jul 2020

Varying immune system responses can predict severe COVID-19 outcomes

The differing immune system responses of patients with COVID-19 can help predict who will experience moderate and severe consequences of disease, according to a new study by Yale researchers published July 27 in the journal Nature.

27 Jul 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

Higher levels of TGFBIp are correlated with severity of COVID-19 symptoms

A new study found raised levels of transforming growth factor beta-induced protein (TGFBIp) in blood sampled from roughly 100 people hospitalized for COVID-19, and further found that elevated levels of both the normal and acetylated forms of TGFBIp correlated with the severity of disease symptoms in these patients.

25 Jul 2020

Combining two immunotherapies into a single treatment found to be more effective

Some of the most promising advances in cancer treatment have centered on immunotherapies that rev up a patient's immune system to attack cancer. But immunotherapies don't work in all patients, and researchers have been searching for ways to increase their effectiveness.

23 Jul 2020

Study uncovers dual role for molecule involved in autoimmune eye disease

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.

23 Jul 2020